Fuji Pharma Co. Ltd

Research Fuji Pharma Co. Ltd (FUP) on Bullrun: valuation model: 17.3% overvalued, market cap EUR 279.48M, P/E 19.8, dividend yield 2.6%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerFUP
ExchangeF
CountryJapan
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CurrencyEUR
Valuation signal17.3% overvalued
Market capEUR 279.48M
P/E19.8
Dividend yield2.6%
Financial periodFY2025
RevenueEUR 51.68B
Revenue growth12.0%
Net incomeEUR 3.00B
Free cash flowEUR 1.95B
Gross margin40.2%

Valuation Snapshot

Bullrun's latest valuation model marks Fuji Pharma Co. Ltd as 17.3% overvalued; latest market cap is EUR 279.48M; P/E is 19.8; dividend yield is 2.6%.

About Fuji Pharma Co. Ltd

Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women, in vitro diagnostics, acute medical care products, and curative medicines, and information regarding pharmaceuticals and health services, as well as contract manufacturing services. Fuji Pharma Co., Ltd.

Frequently asked questions

Is Fuji Pharma Co. Ltd overvalued or undervalued?

Bullrun's valuation model currently marks Fuji Pharma Co. Ltd as 17.3% overvalued.

What is Fuji Pharma Co. Ltd's market cap?

Fuji Pharma Co. Ltd's market capitalization is EUR 279.48M.

What is Fuji Pharma Co. Ltd's P/E ratio?

Fuji Pharma Co. Ltd's price-to-earnings (P/E) ratio is 19.8.

Does Fuji Pharma Co. Ltd pay a dividend?

Fuji Pharma Co. Ltd has a dividend yield of 2.6%.